Navigation Links
Plato BioPharma Presenting Poster at the American Thoracic Society Conference
Date:5/4/2011

WESTMINSTER, Colo., May 4, 2011 /PRNewswire/ -- Plato BioPharma, Inc. (PBI) and Gilead Sciences, Inc. will be jointly presenting a thematic poster at the "Novel Therapeutics in Pulmonary Fibrosis" session at the 2011 American Thoracic Society (ATS) International Conference in Denver, Colorado on May 18, 2011.  The poster entitled Differing Effects of Ambrisentan and Bosentan on Pulmonary Fibrosis and Lung Mechanics Following Bleomycin Instillation will be presented by John Liles, PhD of Gilead Sciences, Inc. and  Craig Plato, PhD, CEO of Plato BioPharma, Inc.

"Human Idiopathic Pulmonary Fibrosis has no known effective treatment, and a dramatically poor prognosis," said Dr. Plato.  "The thematic research being presented at the 2011 ATS Conference provides insights into differential benefit of selective versus non-selective endothelin receptor antagonists in a robust preclinical model of this debilitating disease.  Importantly, for the first time, clinically-relevant functional endpoints such as arterial blood gases, lung function, and pulmonary hemodynamics have been utilized, in part, to reveal the benefit of selective endothelin receptor antagonism."

"One of PBI's key strengths is to leverage and impart our years of experience, expertise, and technology for every study we conduct.  This approach offers clients an advantage over a typical contract research organization or functional service provider relationship.  We strive to be an integral partner with our clients, delivering cutting-edge, high-resolution disease modeling and methods as well as insightful solutions to preclinical drug discovery challenges," said Dr. Plato.  "I believe our joint presentation with Gilead at this year's ATS shows our commitment to these goals and value-add for our clients."

Founded in 2009, Plato BioPharma, Inc is a leading preclinical contract research organization (CRO).  The company offers expert drug discovery and development capabilities in cardiovascular, renal, pulmonary, and hepatic disease therapeutic areas.  PBI provides an integrated research platform from the in-life phase through clinical chemistry, biomarker and histological analyses.  The company specializes in custom study design and execution engagements ranging from pharmacokinetics through disease model and proof-of-concept evaluation.  PBI is headquartered in Westminster, Colorado.


'/>"/>
SOURCE Plato BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ticagrelor Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Trial
2. New PLATO Sub-Analysis of CABG Patients Presented at ACC
3. Plato BioPharma, Inc Appoints New Board Member
4. Plato BioPharma, Inc. Sponsors Novel Disease Model Award
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
8. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
9. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
10. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
11. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... at the Cowen and Company 37 th Annual ... on Tuesday, March 7, 2017 at 11:20 a.m. Eastern ... presentation can be accessed at http://wsw.com/webcast/cowen38/zbh .  The ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:2/24/2017)... 24, 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Dry eye Drugs Price Analysis and Strategies ... eye market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Dry eye ...
(Date:2/24/2017)... Feb. 24, 2017 Medical information groups ... increase their self-service capabilities to manage inquiries from ... New research from consulting leader Best ... developed self-service website portals where HCPs can sign ... one of many findings to emerge from the ...
Breaking Medicine Technology:
(Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... serving San Francisco and environs, is proud to announce an upgrade to the ... on the upgraded Yelp page on topics as diverse as Platelet Rich Plasma ...
(Date:2/26/2017)... ... February 26, 2017 , ... Today, ... the 7th Edition of International Social Design Awards. , The 7th A' ... System Designers, Governments and Institutions worldwide with realized projects and conceptual works. , ...
(Date:2/26/2017)... ... February 26, 2017 , ... LatitudeC Baby Products, an innovative ... it would be offering some it’s exclusive product line to the public through ... unique baby clothing/feeding products, will team up with AMAZON to distribute a limited ...
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... ODH, Inc.™ ... Care Summit, February 27-28 at the Sheraton Pentagon City Hotel in Arlington, VA. ODH’s ... PerformCARE to use behavioral health analytics to improve Medicaid population health management. , ODH ...
(Date:2/25/2017)... ... February 25, 2017 , ... FCPX users now have the ability to ... Studios. With ProSharpen Color users have total control over sharpening amount, sharpening radius, threshold, ... With color spectrum tools users can visually see the color range effected with ease ...
Breaking Medicine News(10 mins):